The Board of Directors of Neuraxis, Inc. authorized and the Company declared a stock dividend on the Company’s Series B Preferred Stock, par value $0.001 per…
Neuraxis, INC (NRXS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On October 14, 2026, the Board of Directors of Neuraxis, Inc. (the “ Company ”) authorized and the Company declared a stock dividend on the Company’s Series B Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”) for the third quart
How this was made
The 30-second read
Why it matters
The issuance of ~81,300 new common shares will dilute existing equity, likely exerting modest downward pressure on the share price ahead of the Oct 30 payment date.
Market read
A micro‑cap corporate action with limited broader market effect; relevance primarily to current shareholders and short‑term traders.
What to watch
Potential tax implications for preferred shareholders and the cash payout for fractional shares.
Background
Neuraxis filed an 8‑K on Oct 14 2026 announcing a stock dividend on its Series B Preferred Stock, converting accrued dividends into common shares.
Ticker impact
SEC 8‑K reports Neuraxis authorizing a stock dividend on its Series B Preferred, issuing ~81,300 common shares payable Oct 30 2026.
likely slight pressure as market prices in the dilution from the dividend issuance
The filing is the first public disclosure of the dividend; the amount of new shares is small but represents a dilution event for a micro‑cap.
Market effects
Minimal impact on the broader biotech sector; only affects Neuraxis shareholders.
None
None
Counterpoint
The dividend could be seen as a positive signal of cash flow stability, potentially supporting the stock.
Key entities
- companyNeuraxis, Inc.
Biotech firm issuing a stock dividend on its Series B Preferred.
